Biology of Blood and Marrow Transplantation
Volume 10, Issue 3 , Pages 178-185 , March 2004

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation

  • Daniel R Couriel

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • Corresponding Author Information Correspondence and reprint requests: Daniel R. Couriel, MD, Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095 USA
    • ,
  • Rima M Saliba

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Sergio Giralt

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Issa Khouri

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Borje Andersson

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Marcos de Lima

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Chitra Hosing

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Paolo Anderlini

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Michelle Donato

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Karen Cleary

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • James Gajewski

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Joyce Neumann

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Cindy Ippoliti

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Gabriela Rondon

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Agueda Cohen

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Richard Champlin

      Affiliations

    • Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

Received 2 July 2003 ,Accepted 23 October 2003.

  • Image Result

    Cumulative incidence of acute GVHD. Patients receiving nonmyeloablative regiments were compared with those receiving myeloablative regimens. Progression of malignancy, immunosuppression withdrawal, do

    Cumulative incidence of acute GVHD. Patients receiving nonmyeloablative regiments were compared with those receiving myeloablative regimens. Progression of malignancy, immunosuppression withdrawal, donor lymphocyte infusion, and death without GVHD were considered competing risks.

  • Image Result
    Cumulative incidence of chronic GVHD. Patients receiving nonmyeloablative regimens were compared with those receiving busulfan/cyclophosphamide and fludarabine/melphalan. Progression of malignancy, im

    Cumulative incidence of chronic GVHD. Patients receiving nonmyeloablative regimens were compared with those receiving busulfan/cyclophosphamide and fludarabine/melphalan. Progression of malignancy, immunosuppression withdrawal, donor lymphocyte infusion, and death without GVHD were considered competing risks.

  • Image Result
    Cumulative incidence of all GVHD. Patients receiving nonmyeloablative (NMA) regimens were compared with those receiving myeloablative (MA) regimens. Only mortality was considered a competing risk. Pat

    Cumulative incidence of all GVHD. Patients receiving nonmyeloablative (NMA) regimens were compared with those receiving myeloablative (MA) regimens. Only mortality was considered a competing risk. Patients undergoing immunosuppression withdrawal, DLI, or both were included in both the NMA (n = 44) and MA (n = 29) groups.

PII: S1083-8791(03)00419-1

doi: 10.1016/j.bbmt.2003.10.006

Biology of Blood and Marrow Transplantation
Volume 10, Issue 3 , Pages 178-185 , March 2004

Article Tools

* Image Usage & Resolution